Does Emgality Cause High Blood Pressure?
Emgality (galcanezumab), a CGRP inhibitor for migraine prevention, lists hypertension as a possible side effect in its prescribing information, but clinical trials showed no significant increase in blood pressure compared to placebo.[1] Post-marketing reports include cases of hypertension, though causality isn't established.
What Do Clinical Trial Data Show?
In pivotal trials (e.g., EVOLVE-1, EVOLVE-2, REGAIN), blood pressure changes were similar between Emgality and placebo groups. Mean systolic blood pressure rose by about 0.5-1 mmHg in treated patients, with no notable hypertensive events driving discontinuations.[2][3] No dose-dependent effect appeared at 120mg or 240mg monthly doses.
What About Real-World Reports?
FDA adverse event data via FAERS logs over 1,000 hypertension reports linked to Emgality since approval in 2018, but these are unverified and don't prove causation—rates are low relative to millions of prescriptions.[4] Patient forums like Drugs.com note occasional complaints of elevated readings, often transient and tied to migraine stress rather than the drug.[5]
Who Might Be at Risk?
People with pre-existing hypertension or on blood pressure meds report monitoring needs, as CGRP blockers can theoretically affect vascular tone. Label advises caution in cardiovascular disease; no black-box warning exists.[1] Migraineurs often have comorbid hypertension, complicating attribution.
How Does It Compare to Other Migraine Preventives?
Unlike some triptans that acutely raise blood pressure, Emgality's monthly injection shows minimal vascular impact. Aimovig (erenumab) had similar trial profiles but more hypertension signals in early data; Nurtec (rimegepant) has fewer reports.[6] Beta-blockers like propranolol, used off-label for migraines, directly lower blood pressure.
What Should Patients Do?
Track blood pressure before and during treatment. Consult a doctor if readings exceed 140/90 mmHg persistently. No routine monitoring is mandated, but those with hypertension history may need closer follow-up.[1]
[1]: Emgality Prescribing Information (FDA)
[2]: NEJM: EVOLVE-1 Trial (2017)
[3]: Lancet: REGAIN Trial (2018)
[4]: FDA FAERS Public Dashboard
[5]: Drugs.com Emgality Reviews
[6]: Aimovig Prescribing Information (FDA)